BR112020004506A2 - mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias - Google Patents

mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias Download PDF

Info

Publication number
BR112020004506A2
BR112020004506A2 BR112020004506-3A BR112020004506A BR112020004506A2 BR 112020004506 A2 BR112020004506 A2 BR 112020004506A2 BR 112020004506 A BR112020004506 A BR 112020004506A BR 112020004506 A2 BR112020004506 A2 BR 112020004506A2
Authority
BR
Brazil
Prior art keywords
mazindole
drug
heroin
paired
substance
Prior art date
Application number
BR112020004506-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander C. Zwyer
Original Assignee
Nls-1 Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nls-1 Pharma Ag filed Critical Nls-1 Pharma Ag
Publication of BR112020004506A2 publication Critical patent/BR112020004506A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112020004506-3A 2017-09-07 2018-09-06 mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias BR112020004506A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555469P 2017-09-07 2017-09-07
US62/555,469 2017-09-07
PCT/IB2018/001138 WO2019058172A1 (en) 2017-09-07 2018-09-06 MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES

Publications (1)

Publication Number Publication Date
BR112020004506A2 true BR112020004506A2 (pt) 2020-09-15

Family

ID=64316589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004506-3A BR112020004506A2 (pt) 2017-09-07 2018-09-06 mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias

Country Status (9)

Country Link
US (1) US11596622B2 (https=)
EP (1) EP3678661A1 (https=)
JP (1) JP7593619B2 (https=)
KR (1) KR20200085730A (https=)
CN (1) CN111343979A (https=)
BR (1) BR112020004506A2 (https=)
CA (1) CA3074054A1 (https=)
MX (1) MX2020002560A (https=)
WO (1) WO2019058172A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217987A (en) 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
WO2009029308A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
JP2013523757A (ja) 2010-03-31 2013-06-17 スパーナス ファーマシューティカルズ インコーポレイテッド マジンドールの製剤
US9687445B2 (en) * 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
JP6584745B2 (ja) 2014-04-09 2019-10-02 和久 前田 抗肥満薬の効果を向上させる組成物の製造方法。
ES2884973T3 (es) 2016-03-09 2021-12-13 Nls Pharmaceutics Ag Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD)

Also Published As

Publication number Publication date
CA3074054A1 (en) 2019-03-28
US11596622B2 (en) 2023-03-07
EP3678661A1 (en) 2020-07-15
US20210161865A1 (en) 2021-06-03
JP2020533295A (ja) 2020-11-19
MX2020002560A (es) 2020-07-13
WO2019058172A1 (en) 2019-03-28
JP7593619B2 (ja) 2024-12-03
CN111343979A (zh) 2020-06-26
KR20200085730A (ko) 2020-07-15

Similar Documents

Publication Publication Date Title
KR101688996B1 (ko) 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
US4939175A (en) Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
KR20200033308A (ko) 유기 화합물
US6512009B1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
JP2010504337A (ja) イヌの認知機能障害症候群の治療のためのディメボン（ｄｉｍｅｂｏｎ）などの水素化ピリド［４，３−ｂ］インドール
RU2403030C2 (ru) ПРОИЗВОДНЫЕ α-АМИНОАМИДА, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ СИНДРОМА УСТАЛЫХ НОГ И ВЫЗЫВАЮЩИХ ПРИВЫКАНИЕ РАССТРОЙСТВ
JP2023520912A (ja) ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
HK1247847A1 (zh) 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CA3069462A1 (en) Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
BR112020004506A2 (pt) mazindol para uso no tratamento de distúrbio de uso de substâncias, composição compreendendo mazindol, método de tratamento de distúrbio de abuso de substâncias
ES2591354T3 (es) Tapentadol para su uso en el tratamiento del síndrome de intestino irritable
JPWO2019004292A1 (ja) セロトニン３受容体アゴニストによる疼痛の治療
EA032511B1 (ru) Средство для лечения дисфункции лобной доли
HK1173379B (en) Compositions comprising tramadol and celecoxib in the treatment of pain

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]